ORIC PEER ANALYSIS

Oric Pharmaceuticals Inc — metric-by-metric comparison with peers and the industry median

ORICOric Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
ORICIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
ORIC+9.3%MSB+27.6%TLX-29.5%CSL-48.2%RTALB+24.1%
Year-to-Date (YTD)
ORIC+42.3%MSB-24.3%TLX+50.7%CSL-28.5%RTALB+5.0%

Key Metric Comparison

P/E

Lower is better
ORICMSBTLXCSL29.44RTALB4.89Median 17.91

ROE

Higher is better
ORIC-42.6%MSB-11.3%TLX-1.8%CSL7.7%RTALB15.1%Median -47.5%

Net Margin

Higher is better
ORICMSB-115.3%TLX-0.9%CSL9.2%RTALB136.3%Median -125.7%

Revenue Growth

Higher is better
ORIC-100.0%MSB410.4%TLX56.3%CSL4.8%RTALB24.0%Median 5.1%

All Metrics

Valuation
MetricORICMSBTLXCSLRTALBInd. Median
P/E29.444.8917.91
P/B2.956.372.200.613.51
EV/EBITDA120.1410.2174.6114.82
P/S31.613.242.626.6710.89
Financial Health
MetricORICMSBTLXCSLRTALBInd. Median
Current Ratio16.331.432.571.215.90
Debt/Equity0.8%112.3%67.4%1.2%10.9%
NetDebt/EBITDA2.0813.132.220.901.15
Profitability
MetricORICMSBTLXCSLRTALBInd. Median
Net Margin-115.3%-0.9%9.2%136.3%-125.7%
ROE-42.6%-11.3%-1.8%7.7%15.1%-47.5%
ROA-39.8%-8.6%-0.7%3.8%13.1%-35.8%
EBITDA Margin-76.6%3.0%32.8%9.0%-105.8%
Growth + Dividend
MetricORICMSBTLXCSLRTALBInd. Median
Rev. Growth-100.0%410.4%56.3%4.8%24.0%5.1%
NI Growth-39.4%134.0%12.1%
Div. Yield0.0%2.5%0.0%0.2%
Payout0.0%103.1%0.0%0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on ORIC

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.